Eid2 - EP300 interacting inhibitor of differentiation 2

Predicted to enable SMAD binding activity and transcription corepressor activity. Predicted to be involved in several processes, including negative regulation of transcription, DNA-templated; negative regulation of transforming growth factor beta receptor signaling pathway; and transmembrane receptor protein serine/threonine kinase signaling pathway. Predicted to be active in nucleoplasm. Orthologous to human EID2 (EP300 interacting inhibitor of differentiation 2). [provided by Alliance of Genome Resources, Apr 2022]